Veterinary compounding in Malaysia — what prescribing vets should know about customised animal formulations (non‑sterile only)

Short answer: Compounded, non‑sterile formulations are a useful tool in veterinary practice when licensed products do not meet a patient’s species‑specific dose, route or excipient needs. The central clinical considerations are species differences in pharmacokinetics and toxicology, formulation‑specific excipient hazards (notably for cats and small species), and transdermal/mucosal absorption variability across species and body sites. Prescribers should therefore document the clinical rationale, pick formulation attributes that match the species and indication, and monitor for efficacy and species‑specific adverse events.

Why compounding matters in veterinary practice

Veterinary patients span multiple species with different metabolic pathways, body sizes and tolerances for excipients commonly used in human medicine. A single tablet cut into smaller pieces is often an inadequate dosing strategy; compounding allows dose precision, palatable flavours, and appropriate vehicles for the intended route of administration. Reviews summarise the regulatory and practical challenges around veterinary compounding and list resources clinicians can consult for safe practice (Veterinary Compounding: Regulation, Challenges, and Resources. Pharmaceutics, 2017. https://pubmed.ncbi.nlm.nih.gov/28075379/). Limitation: regulatory context differs by country.

Species‑specific pharmacology and safety considerations

Some well‑known species differences with direct prescribing implications:

• Cats and glucuronidation limitations: cats conjugate certain drugs poorly and can form toxic metabolites. For example, cat sensitivity to some excipients and to drugs that undergo glucuronidation requires careful selection of both active and vehicle.
• Xylitol in dogs: xylitol causes rapid insulin release and hypoglycaemia in dogs and can lead to hepatic injury; it is a household item often accidentally given to dogs, and inclusion of xylitol as a sweetener in a compounded veterinary product is dangerous for dogs (Xylitol toxicity in dogs. Compendium, 2010. https://pubmed.ncbi.nlm.nih.gov/20473849/; Xylitol Toxicosis in Dogs: An Update. Vet Clin North Am Small Anim Pract, 2018. https://pubmed.ncbi.nlm.nih.gov/30064708/). Limitations: reviews summarise case series and toxicology data rather than RCTs.
• Propylene glycol and cats: propylene glycol can cause Heinz‑body haemolytic anaemia and D‑lactic acidosis in cats when exposures are substantial; avoid high concentrations of propylene glycol‑containing vehicles in feline formulations (Contribution of propylene glycol‑induced Heinz body formation to anemia in cats. JAVMA, 1989. https://pubmed.ncbi.nlm.nih.gov/2708106/; A toxicological review of the propylene glycols. Critical Reviews in Toxicology, 2013. https://pubmed.ncbi.nlm.nih.gov/23656560/). Limitation: older toxicology data and experimental dosing.

Transdermal and local absorption — not one size fits all

Transdermal absorption varies by species, skin site and formulation. Key points from the literature:

• Comparative and in vitro studies show marked differences in skin thickness and permeation across species and body sites; do not extrapolate human patch data to animals without species‑specific evidence (Interspecies analysis of comparative histologic thickness and blood flow; J Invest Dermatol, 1990. https://pubmed.ncbi.nlm.nih.gov/2230221/; The percutaneous permeation of antiseptic combinations through skin of different species in vitro; BMC Vet Res, 2011. https://pubmed.ncbi.nlm.nih.gov/21835019/). Limitation: in vitro and comparative data; clinical translation requires caution.
• Feline pinna (inner ear) skin has been used experimentally as a route for transdermal drug delivery with specific formulations; ex‑vivo absorption studies demonstrate both the potential and variability of this approach (Ex‑vivo percutaneous absorption of a tramadol formulation through feline inner pinna skin. Research in Vet Science, 2022. https://pubmed.ncbi.nlm.nih.gov/35868201/). Limitation: ex‑vivo work may not fully predict in vivo kinetics.
• Topical patch pharmacokinetics can be measured in cats — e.g., lidocaine patch studies indicate measurable systemic absorption and thus the need for species‑appropriate dosing and safety checks (Pharmacokinetics of lidocaine following 5% patches in cats. J Vet Pharmacol Ther, 2008. https://pubmed.ncbi.nlm.nih.gov/18638297/). Limitation: small PK studies; monitoring advised for systemic effects.

Excipient selection and palatability

Excipient choice is as clinically important as the active in many veterinary compounds. Examples:

• Sweeteners safe in humans may be toxic in animals (xylitol in dogs).
• High levels of propylene glycol can be risky in cats; consider alternate solvents or aqueous suspensions where possible.
• Flavours improve compliance but must be chosen for the species (fish or poultry flavours for cats, chicken or beef for dogs) and checked for allergenic or toxic ingredients.

Prescription writing and monitoring checklist for vets

When requesting a compounded non‑sterile product, include:

• Species, weight and clinical diagnosis.
• Active ingredient (generic name), desired dose and dosing interval, route and intended duration.
• Any excipient exclusions (e.g., “no xylitol”, “no propylene glycol for cats”).
• Target formulation properties (flavour, vehicle type — e.g., suspension, paste, transdermal matrix) and any stability or palatability preferences.
• Monitoring plan and plan to report adverse events.

Regulatory and safety framing (practical)

Compounded veterinary medicines are tools for tailored care but require informed risk‑benefit thinking. Use published toxicology and PK data for the target species when available; where only in vitro or ex‑vivo data exist, adopt conservative monitoring and dosing. For regulatory and policy context and broad guidance on veterinary compounding, see Veterinary Compounding: Regulation, Challenges, and Resources (Pharmaceutics, 2017). https://pubmed.ncbi.nlm.nih.gov/28075379/ (review; jurisdictional variation applies).

Selected clinical and safety references (inline in the text)

• Xylitol toxicity in dogs. Compendium, 2010. https://pubmed.ncbi.nlm.nih.gov/20473849/ (review of toxicosis cases).
• Xylitol Toxicosis in Dogs: An Update. Vet Clin North Am Small Anim Pract, 2018. https://pubmed.ncbi.nlm.nih.gov/30064708/ (update review).
• Contribution of propylene glycol‑induced Heinz body formation to anemia in cats. JAVMA, 1989. https://pubmed.ncbi.nlm.nih.gov/2708106/ (experimental/clinical observations in cats).
• A toxicological review of the propylene glycols. Critical Reviews in Toxicology, 2013. https://pubmed.ncbi.nlm.nih.gov/23656560/ (comprehensive toxicology review).
• Ex‑vivo study of the percutaneous absorption of a tramadol formulation through feline inner pinna skin. Research in Veterinary Science, 2022. https://pubmed.ncbi.nlm.nih.gov/35868201/ (ex‑vivo absorption study).
• Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. Journal of Veterinary Pharmacology and Therapeutics, 2008. https://pubmed.ncbi.nlm.nih.gov/18638297/ (PK after patch application in cats).
• The percutaneous permeation of a combination … through skin of different species in vitro. BMC Vet Res, 2011. https://pubmed.ncbi.nlm.nih.gov/21835019/ (in vitro species comparison).
• Interspecies and interregional analysis of comparative histologic thickness and blood flow measurements at five cutaneous sites in nine species. J Invest Dermatol, 1990. https://pubmed.ncbi.nlm.nih.gov/2230221/ (comparative anatomy paper with practical implications for transdermal dosing).
• Veterinary Compounding: Regulation, Challenges, and Resources. Pharmaceutics, 2017. https://pubmed.ncbi.nlm.nih.gov/28075379/ (review of compounding practice and regulation).

Bottom line for veterinary prescribers

Compounded non‑sterile products enable tailored dosing and compliance solutions in veterinary practice, but they also shift safety considerations from manufacturer testing to clinician judgment about species, excipients and monitoring. Use species‑specific toxicology and pharmacokinetic data to choose vehicles and excipients, document rationale clearly on the prescription, and establish a monitoring plan for efficacy and adverse effects.

WhatsApp us